Fig. 11

Predictive capacity of the signature in immunotherapy response and chemosensitivity. A IPS difference between high- and low-group with different statuses of CTLA-4, PD-1, PD-L1, and PD-L2 (high-risk group: n = 152; low-risk group, n = 152). B The difference in T cells dysfunction score, T cells exclusion score, and TIDE score between the two groups. C Difference in the overall survival between high- and low-risk groups in the IMvigor210 dataset. D Difference in the objective response rate between high- and low-risk group in the IMvigor210 dataset (high-risk group: n = 174; low-risk group, n = 174). E Chemotherapy drugs in cervical cancer with distinct IC50 values between the two groups. F AUC value in GSE168009 cohort. G Response to CCRT based on risk score in GSE168009 cohort (durable clinical benefit, n = 5; no durable benefit, n = 4). IPS immunophenoscore, TIDE tumor immune dysfunction and exclusion, IC50 half-maximum inhibitory concentration, CCRT concurrent chemoradiotherapy, CR complete response, PR partial response, SD stable disease, PD progression dsiease. ***p < 0.001; ****p < 0.0001; ns: nonsignificant